High-CBD Extract (CBD-X) in Asthma Management: Reducing Th2-Driven Cytokine Secretion and Neutrophil/Eosinophil Activity.

IF 4.3 3区医学 Q2 CHEMISTRY, MEDICINAL

Pharmaceuticals Pub Date : 2024-10-17 DOI:10.3390/ph17101382

Miran Aswad, Antonina Pechkovsky, Narmeen Ghanayiem, Haya Hamza, Yaniv Dotan, Igal Louria-Hayon

{"title":"High-CBD Extract (CBD-X) in Asthma Management: Reducing Th2-Driven Cytokine Secretion and Neutrophil/Eosinophil Activity.","authors":"Miran Aswad, Antonina Pechkovsky, Narmeen Ghanayiem, Haya Hamza, Yaniv Dotan, Igal Louria-Hayon","doi":"10.3390/ph17101382","DOIUrl":null,"url":null,"abstract":"Background/objectives: Asthma is a chronic inflammatory disorder of the airways affecting over 10% of the global population. It is characterized by airway inflammation, mucus hypersecretion, and bronchial hyperresponsiveness, driven predominantly by type 2 helper T cells (Th2) and type 2 innate lymphoid cells (ILC2s) in a subset of patients. However, a significant portion of asthmatic individuals present with \"type 2-low\" asthma that is often refractory to standard inhaled corticosteroid (ICS) therapy. Therefore, developing innovative therapeutic strategies has become essential. Recent studies have highlighted cannabidiol (CBD) as a promising anti-inflammatory agent capable of modulating immune responses. This study investigates the therapeutic potential of a high-CBD extract (CBD-X) in asthma.Methods: We evaluated the effects of CBD-X on cells involved in asthma pathogenesis using primary human Th2 cells, neutrophils, and asthma mouse model.Results: Our findings indicate that CBD-X extract inhibits Th2 differentiation and reduces the secretion of IL-5 and IL-13, which are crucial cytokines in asthma. Additionally, CBD-X significantly reduces pro-inflammatory cytokines IL-8 and IL-6 in neutrophils and impairs their migration, a critical step in airway inflammation. In a murine asthma model, CBD-X administration led to marked downregulation of IgE and pro-asthmatic cytokines, along with reduced leukocyte, eosinophil, and neutrophil infiltration in lung tissues.Conclusions: These results suggest that CBD-X extract could offer a novel and complementary approach to managing both type 2-high and type 2-low asthma by targeting key inflammatory pathways and modulating immune cell behavior.","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"17 10","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11510504/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/ph17101382","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/objectives: Asthma is a chronic inflammatory disorder of the airways affecting over 10% of the global population. It is characterized by airway inflammation, mucus hypersecretion, and bronchial hyperresponsiveness, driven predominantly by type 2 helper T cells (Th2) and type 2 innate lymphoid cells (ILC2s) in a subset of patients. However, a significant portion of asthmatic individuals present with "type 2-low" asthma that is often refractory to standard inhaled corticosteroid (ICS) therapy. Therefore, developing innovative therapeutic strategies has become essential. Recent studies have highlighted cannabidiol (CBD) as a promising anti-inflammatory agent capable of modulating immune responses. This study investigates the therapeutic potential of a high-CBD extract (CBD-X) in asthma.

Methods: We evaluated the effects of CBD-X on cells involved in asthma pathogenesis using primary human Th2 cells, neutrophils, and asthma mouse model.

Results: Our findings indicate that CBD-X extract inhibits Th2 differentiation and reduces the secretion of IL-5 and IL-13, which are crucial cytokines in asthma. Additionally, CBD-X significantly reduces pro-inflammatory cytokines IL-8 and IL-6 in neutrophils and impairs their migration, a critical step in airway inflammation. In a murine asthma model, CBD-X administration led to marked downregulation of IgE and pro-asthmatic cytokines, along with reduced leukocyte, eosinophil, and neutrophil infiltration in lung tissues.

Conclusions: These results suggest that CBD-X extract could offer a novel and complementary approach to managing both type 2-high and type 2-low asthma by targeting key inflammatory pathways and modulating immune cell behavior.

查看原文本刊更多论文

高CBD提取物（CBD-X）在哮喘治疗中的应用：降低Th2驱动的细胞因子分泌和中性粒细胞/嗜酸性粒细胞活性

背景/目的：哮喘是一种慢性气道炎症性疾病，影响全球 10%以上的人口。它以气道炎症、粘液分泌过多和支气管高反应性为特征，在一部分患者中主要由 2 型辅助性 T 细胞（Th2）和 2 型先天性淋巴细胞（ILC2s）驱动。然而，相当一部分哮喘患者表现为 "2 型低度 "哮喘，往往对标准吸入皮质类固醇（ICS）疗法无效。因此，开发创新的治疗策略变得至关重要。最近的研究强调大麻二酚（CBD）是一种很有前景的抗炎药物，能够调节免疫反应。本研究调查了高CBD提取物（CBD-X）对哮喘的治疗潜力：我们使用原代人类 Th2 细胞、中性粒细胞和哮喘小鼠模型评估了 CBD-X 对参与哮喘发病机制的细胞的影响：结果：我们的研究结果表明，CBD-X提取物可抑制Th2分化，减少IL-5和IL-13的分泌，而IL-5和IL-13是哮喘的关键细胞因子。此外，CBD-X 还能显著减少中性粒细胞中的促炎细胞因子 IL-8 和 IL-6，并阻碍它们的迁移，而迁移是气道炎症的关键步骤。在小鼠哮喘模型中，服用 CBD-X 能明显降低 IgE 和促哮喘细胞因子，同时减少肺组织中的白细胞、嗜酸性粒细胞和中性粒细胞浸润：这些结果表明，CBD-X 提取物可以通过靶向关键炎症通路和调节免疫细胞行为，为治疗 2 型高哮喘和 2 型低哮喘提供一种新颖的补充方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmaceuticals Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

6.10

自引率

4.30%

发文量

1332

审稿时长

6 weeks

期刊介绍： Pharmaceuticals (ISSN 1424-8247) is an international scientific journal of medicinal chemistry and related drug sciences.Our aim is to publish updated reviews as well as research articles with comprehensive theoretical and experimental details. Short communications are also accepted; therefore, there is no restriction on the maximum length of the papers.